CITIUS PHARMAC (Germany) Performance
| 47N Stock | EUR 3.29 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0681, which signifies not very significant fluctuations relative to the market. As returns on the market increase, CITIUS PHARMAC's returns are expected to increase less than the market. However, during the bear market, the loss of holding CITIUS PHARMAC is expected to be smaller as well. At this point, CITIUS PHARMAC DL has a negative expected return of -1.49%. Please make sure to confirm CITIUS PHARMAC's maximum drawdown, potential upside, and the relationship between the jensen alpha and value at risk , to decide if CITIUS PHARMAC DL performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CITIUS PHARMAC DL has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
CITIUS |
CITIUS PHARMAC Relative Risk vs. Return Landscape
If you would invest 1,083 in CITIUS PHARMAC DL on September 17, 2024 and sell it today you would lose (754.00) from holding CITIUS PHARMAC DL or give up 69.62% of portfolio value over 90 days. CITIUS PHARMAC DL is currently producing negative expected returns and takes up 7.8865% volatility of returns over 90 trading days. Put another way, 70% of traded stocks are less volatile than CITIUS, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CITIUS PHARMAC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CITIUS PHARMAC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CITIUS PHARMAC DL, and traders can use it to determine the average amount a CITIUS PHARMAC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1894
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 47N |
Estimated Market Risk
| 7.89 actual daily | 70 70% of assets are less volatile |
Expected Return
| -1.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CITIUS PHARMAC is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CITIUS PHARMAC by adding CITIUS PHARMAC to a well-diversified portfolio.
CITIUS PHARMAC Fundamentals Growth
CITIUS Stock prices reflect investors' perceptions of the future prospects and financial health of CITIUS PHARMAC, and CITIUS PHARMAC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CITIUS Stock performance.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.16 | |||
| Shares Outstanding | 146.21 M | |||
| EBITDA | (33.31 M) | |||
| Cash And Equivalents | 115.66 M | |||
| Cash Per Share | 0.79 X | |||
| Total Debt | 1.06 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.70 X | |||
| Cash Flow From Operations | (22.02 M) | |||
| Earnings Per Share | (0.19) X | |||
About CITIUS PHARMAC Performance
By analyzing CITIUS PHARMAC's fundamental ratios, stakeholders can gain valuable insights into CITIUS PHARMAC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CITIUS PHARMAC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CITIUS PHARMAC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. CITIUS PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 10 people.Things to note about CITIUS PHARMAC DL performance evaluation
Checking the ongoing alerts about CITIUS PHARMAC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CITIUS PHARMAC DL help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CITIUS PHARMAC DL generated a negative expected return over the last 90 days | |
| CITIUS PHARMAC DL has high historical volatility and very poor performance | |
| CITIUS PHARMAC DL has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (23.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CITIUS PHARMAC DL has accumulated about 115.66 M in cash with (22.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.79. |
- Analyzing CITIUS PHARMAC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CITIUS PHARMAC's stock is overvalued or undervalued compared to its peers.
- Examining CITIUS PHARMAC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CITIUS PHARMAC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CITIUS PHARMAC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CITIUS PHARMAC's stock. These opinions can provide insight into CITIUS PHARMAC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CITIUS Stock analysis
When running CITIUS PHARMAC's price analysis, check to measure CITIUS PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CITIUS PHARMAC is operating at the current time. Most of CITIUS PHARMAC's value examination focuses on studying past and present price action to predict the probability of CITIUS PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CITIUS PHARMAC's price. Additionally, you may evaluate how the addition of CITIUS PHARMAC to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |